Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch [Yahoo! Finance]
Alumis Inc. (ALMS)
Company Research
Source: Yahoo! Finance
Most Read from Bloomberg How Air Conditioning Took Over the American Office Hong Kong's Arts Hub Turns to Selling Land to Stay Afloat The Outsized Cost of Expanding US Roads Drug developers that have raised more than $10 million in US initial public offerings this year have largely faltered with six of the 11 firms diving below their debut prices and the median decliner trading 45% below the offer price, data compiled by Bloomberg show. The likes of BioAge Labs Inc. and MBX Biosciences Inc. will seek to buck that trend with industry bankers and lawyers saying the market's reaction to the next batch will signal whether others can get through the door this year or at the start of 2025. “A stable or uptick in the stock of the four that will launch in September would have a tailwind effect,” for the companies that could debut this year or wait till 2025, said Seo Salimi, co-head of the equity capital markets practice at law firm Paul Hastings LLP. For Bicara Therapeutics In
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024GlobeNewswire
- Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $30.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements [Yahoo! Finance]Yahoo! Finance
- Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent AchievementsGlobeNewswire
ALMS
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 8/27/24 - Form SC
- ALMS's page on the SEC website